Quantum X Labs Ltd. Acquired, Holds AI-Quantum Error Correction Patent

Viewbix Inc. has undergone a complete corporate transformation, rebranding as Quantum X Labs Inc. effective April 30, 2026, and shifting its focus to quantum computing following the March 2026 acquisition of Quantum X Labs Ltd. This is more than the addition of a new division; the company, now trading under the ticker “QXL,” intends to become a leader in researching and commercializing quantum solutions for sectors ranging from navigation to drug discovery. Central to this strategy is a pending patent for “AI-Quantum Error Correction,” a novel approach to stabilizing quantum computations, and a portfolio of subsidiary companies developing practical applications. These include Quantum Gyro, a 40%-owned subsidiary, which is creating gyroscope chip technology designed to function in environments where GPS signals are unavailable, indicating a move toward military and security applications.

Quantum X Labs Rebranding & Core Technology Focus

The recent strategic shift of Viewbix Inc. into quantum computing is underscored by its rebranding as Quantum X Labs Inc. (“QXL”), a move signaling a complete departure from its origins in digital advertising. The name and ticker change to “QXL” will be effective April 30, 2026. This approach, combining artificial intelligence with established error correction methods, could provide a competitive advantage in the quantum computing field. Other subsidiaries, such as Quantum Atom Accuracy and Nuclear Quantum, are advancing atomic clocks and quantum simulation algorithms, respectively, targeting precision timing and industries like nuclear engineering. While prioritizing quantum innovation, Quantum X Labs will continue to support its existing digital advertising businesses through subsidiaries Gix Media Ltd. and Metagramm Software Ltd., creating a diversified portfolio that balances long-term quantum development with current revenue streams.

Portfolio Companies: Quantum Gyro, Atom Accuracy & Nuclear Quantum

The pursuit of practical quantum technologies is diversifying beyond fundamental research, with a growing number of companies focusing on specific applications. Complementing this focus on navigation is Quantum Atom Accuracy, a wholly-owned subsidiary advancing atomic clock technology. These clocks utilize novel light-modulation schemes to achieve high accuracy, robustness, and enhanced coherence for precision timing solutions, a level of performance vital for applications ranging from financial trading to scientific instrumentation. The portfolio also includes Nuclear Quantum, a 40%-owned subsidiary, which is concentrating on quantum-powered simulation algorithms aimed at the nuclear and engineering industries; recent progress indicates movement toward commercial engagement with leading simulation providers, suggesting a strategy of collaborative development and early market access. Beyond these core areas, subsidiaries like QuantumQ Security, Quantum Transportation, and CliniQuantum are exploring quantum applications in cybersecurity, advanced error correction, and drug discovery, demonstrating a broad commitment to harnessing quantum mechanics across multiple disciplines.

Applications of Quantum Technologies: Security, Transport & Drug Discovery

The recent corporate rebranding of Viewbix as Quantum X Labs Inc. (“QXL”) signals a determined push into applied quantum technologies, extending beyond fundamental research into areas like secure navigation and pharmaceutical innovation. This is not simply about theoretical advancement; the company is actively pursuing solutions for real-world challenges in positioning and navigation. Beyond security, Quantum X Labs is also targeting improvements in transportation and drug discovery. Quantum Transportation, a 30%-owned subsidiary, is developing transformer-based quantum decoder technology, with potential applications in advanced error correction and secure systems. Simultaneously, CliniQuantum, in which Quantum X Labs holds a 46% stake, is applying quantum-enhanced methods, such as Markov Chain Monte Carlo, to accelerate processes within drug discovery, clinical trial optimization, and biomedicine. The company stated that it is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments, as well as developing quantum-based GPS replacement and quantum atom accuracy solutions, highlighting a diverse range of commercial ambitions. This approach, the company believes, will be crucial for realizing the full potential of quantum technologies.